|The VEGF-A vegfa (Catalog #MBS691187) is an Antibody produced from Goat and is intended for research purposes only. The product is available for immediate purchase. The Goat Anti-Human VEGF-A reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s VEGF-A can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB), Neutr.
Western Blot: To detect human VEGF-A by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant human VEGF-An is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.`. Researchers should empirically determine the suitability of the VEGF-A vegfa for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The VEGF-A vegfa product has the following accession number(s) (GI #76781480) (NCBI Accession #NP_001020537.2) (Uniprot Accession #P15692). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.
Antibody Generation: Produced from sera of goats pre-immunized with highly pure (>98%) recombinant hVEGF. Anti-hVEGF specific antibody was purified by affinity chromatography employing immobilized hVEGF matrix.